Literature DB >> 9176441

Increased angiotensin II in ascites during severe ovarian hyperstimulation syndrome: role of early pregnancy and ovarian gonadotropin stimulation.

A Delbaere1, P J Bergmann, C Gervy-Decoster, M Deschodt-Lanckman, V de Maertelaer, M Staroukine, M Camus, Y Englert.   

Abstract

OBJECTIVE: To investigate the implications of the ovarian renin-angiotensin system (RAS) in the pathophysiology of the ovarian hyperstimulation syndrome (OHSS) in relation to gonadotropin stimulation and early pregnancy.
DESIGN: A controlled clinical study comparing blood and simultaneously sampled peritoneal fluid (PF) from patients with severe OHSS and from controls without OHSS.
SETTING: University Hospitals. PATIENT(S): Eleven patients with severe OHSS, 8 patients with ascites of other origin, 9 patients with a first-trimester pregnancy, and 15 patients stimulated with gonadotropins for IVF. MAIN OUTCOME MEASURE(S): Angiotensin II immunoreactivity was measured in blood and PF and analyzed by high-performance liquid chromatography (HPLC) in ascites from OHSS. RESULT(S): Angiotensin II immunoreactivity (pg/mL; mean +/- SE) was highest in the ascites from pregnant OHSS (1,669 +/- 418), reaching levels 5 times higher than in the plasma (331 +/- 61) and 100 times higher than in control ascites (17 +/- 6.7). Angiotensin II immunoreactivity was elevated in the PF during early pregnancy (211 +/- 68) and after gonadotropin stimulation (244 +/- 41) and was higher than in the plasma in both groups. Analysis by HPLC showed that the majority of Ang II immunoreactivity in the ascites of OHSS was because of true Ang II. CONCLUSION(S): Severe forms of OHSS, especially those associated with pregnancy, are consistently characterized by huge concentrations of Ang II immunoreactivity in the ascites, proved to be true Ang II by HPLC analysis. This may be due to the synergistic effects of exogenous and endogenous hCG on the ovarian RAS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176441     DOI: 10.1016/s0015-0282(97)81436-7

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Understanding ovarian hyperstimulation syndrome.

Authors:  Anne Delbaere; Guillaume Smits; Anne De Leener; Sabine Costagliola; Gilbert Vassart
Journal:  Endocrine       Date:  2005-04       Impact factor: 3.633

2.  Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization.

Authors:  Stephen R Lincoln; Michael S Opsahl; Keith L Blauer; Susan H Black; Joseph D Schulman
Journal:  J Assist Reprod Genet       Date:  2002-04       Impact factor: 3.412

3.  Risk of Higher Blood Pressure in 3 to 6 Years Old Singleton Born From OHSS Patients Undergone With Fresh IVF/ICSI.

Authors:  Yimin Zhu; Yanling Fu; Minyue Tang; Huanmiao Yan; Fanghong Zhang; Xiaoling Hu; Guofang Feng; Yu Sun; Lanfeng Xing
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-05       Impact factor: 6.055

Review 4.  New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?

Authors:  A Delbaere; G Smits; O Olatunbosun; R Pierson; G Vassart; S Costagliola
Journal:  Hum Reprod       Date:  2004-01-29       Impact factor: 6.918

5.  Outpatient Management of Severe Ovarian Hyperstimulation Syndrome (OHSS) with Placement of Pigtail Catheter.

Authors:  M Abuzeid; H Warda; S Joseph; M G Corrado; Y Abuzeid; M Ashraf; B Rizk
Journal:  Facts Views Vis Obgyn       Date:  2014

6.  Spontaneous ovarian hyperstimulation syndrome in a triplet pregnancy.

Authors:  Nisha Rani Agrawal; Garima Gupta; Kusum Verma; Neeraj Varyani
Journal:  Case Rep Crit Care       Date:  2012-10-08

7.  Spontaneous ovarian hyperstimulation syndrome following a thawed embryo transfer cycle.

Authors:  Mi Kyoung Kim; Hyung Jae Won; Sung Han Shim; Dong Hyun Cha; Tae Ki Yoon
Journal:  Clin Exp Reprod Med       Date:  2014-09-30

8.  Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis.

Authors:  Jing Zhao; Bin Xu; Xi Huang; Yi Yan; Yanping Li
Journal:  Reprod Health       Date:  2020-11-20       Impact factor: 3.223

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.